101 related articles for article (PubMed ID: 23973746)
21. Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis.
Koch M; Ramsaransing GS; Arutjunyan AV; Stepanov M; Teelken A; Heersema DJ; De Keyser J
J Neurol; 2006 Apr; 253(4):483-7. PubMed ID: 16283096
[TBL] [Abstract][Full Text] [Related]
22. Metabolic dysfunctions in multiple sclerosis: implications as to causation, early detection, and treatment, a case control study.
Senanayake VK; Jin W; Mochizuki A; Chitou B; Goodenowe DB
BMC Neurol; 2015 Aug; 15():154. PubMed ID: 26311235
[TBL] [Abstract][Full Text] [Related]
23. Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis.
Booth DR; Arthur AT; Teutsch SM; Bye C; Rubio J; Armati PJ; Pollard JD; Heard RN; Stewart GJ;
J Mol Med (Berl); 2005 Oct; 83(10):822-30. PubMed ID: 16075257
[TBL] [Abstract][Full Text] [Related]
24. Serum uric acid levels in patients with multiple sclerosis: a meta-analysis.
Liu B; Shen Y; Xiao K; Tang Y; Cen L; Wei J
Neurol Res; 2012 Mar; 34(2):163-71. PubMed ID: 22333889
[TBL] [Abstract][Full Text] [Related]
25. A comparison of memory performance in relapsing-remitting, primary progressive and secondary progressive, multiple sclerosis.
Gaudino EA; Chiaravalloti ND; DeLuca J; Diamond BJ
Neuropsychiatry Neuropsychol Behav Neurol; 2001 Jan; 14(1):32-44. PubMed ID: 11234907
[TBL] [Abstract][Full Text] [Related]
26. Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis.
Verbeek MM; Notting EA; Faas B; Claessens-Linskens R; Jongen PJ
Acta Neurol Scand; 2010 May; 121(5):309-14. PubMed ID: 19925532
[TBL] [Abstract][Full Text] [Related]
27. Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness.
Saidha S; Syc SB; Durbin MK; Eckstein C; Oakley JD; Meyer SA; Conger A; Frohman TC; Newsome S; Ratchford JN; Frohman EM; Calabresi PA
Mult Scler; 2011 Dec; 17(12):1449-63. PubMed ID: 21865411
[TBL] [Abstract][Full Text] [Related]
28. sICAM-1 is not a marker for disease activity in the relapse-free interval of multiple sclerosis--a cross-sectional pilot study.
Flachenecker P; Jung S; Rieckmann P; Toyka KV
J Neurol; 2002 Aug; 249(8):1001-3. PubMed ID: 12195444
[TBL] [Abstract][Full Text] [Related]
29. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
[TBL] [Abstract][Full Text] [Related]
30. High copper and low zinc serum levels in Iranian patients with multiple sclerosis: a case control study.
Ghazavi A; Kianbakht S; Ghasami K; Mosayebi G
Clin Lab; 2012; 58(1-2):161-4. PubMed ID: 22372359
[TBL] [Abstract][Full Text] [Related]
31. Cortical dysfunction underlies disability in multiple sclerosis.
Vucic S; Burke T; Lenton K; Ramanathan S; Gomes L; Yannikas C; Kiernan MC
Mult Scler; 2012 Apr; 18(4):425-32. PubMed ID: 21965421
[TBL] [Abstract][Full Text] [Related]
32. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.
Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F
Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691
[TBL] [Abstract][Full Text] [Related]
33. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
34. Use of the PRIMUS scale to assess quality of life in a Spanish population of multiple sclerosis patients.
Hernández MA; Mora S;
Neurologia; 2013; 28(6):340-7. PubMed ID: 23067780
[TBL] [Abstract][Full Text] [Related]
35. Cognitive impairment and decline in different MS subtypes.
Huijbregts SC; Kalkers NF; de Sonneville LM; de Groot V; Polman CH
J Neurol Sci; 2006 Jun; 245(1-2):187-94. PubMed ID: 16643951
[TBL] [Abstract][Full Text] [Related]
36. Progression in multiple sclerosis: further evidence of an age dependent process.
Koch M; Mostert J; Heersema D; De Keyser J
J Neurol Sci; 2007 Apr; 255(1-2):35-41. PubMed ID: 17331540
[TBL] [Abstract][Full Text] [Related]
37. Low degree of cortical pathology is associated with benign course of multiple sclerosis.
Calabrese M; Favaretto A; Poretto V; Romualdi C; Rinaldi F; Mattisi I; Morra A; Perini P; Gallo P
Mult Scler; 2013 Jun; 19(7):904-11. PubMed ID: 23069877
[TBL] [Abstract][Full Text] [Related]
38. A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode.
Tutuncu M; Demirci NO; Özer F; Saip S; Kantarci OH; Siva A
Mult Scler; 2011 Oct; 17(10):1262-4. PubMed ID: 21135019
[TBL] [Abstract][Full Text] [Related]
39. Serum lactate as a novel potential biomarker in multiple sclerosis.
Amorini AM; Nociti V; Petzold A; Gasperini C; Quartuccio E; Lazzarino G; Di Pietro V; Belli A; Signoretti S; Vagnozzi R; Lazzarino G; Tavazzi B
Biochim Biophys Acta; 2014 Jul; 1842(7):1137-43. PubMed ID: 24726946
[TBL] [Abstract][Full Text] [Related]
40. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS.
Sellebjerg F; Börnsen L; Khademi M; Krakauer M; Olsson T; Frederiksen JL; Sørensen PS
Neurology; 2009 Dec; 73(23):2003-10. PubMed ID: 19996075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
